Mitral regurgitation (MR) is the most common heart valve disease, affecting around four million people in the U.S. Typically, open-heart surgeries are a standard mode of treatment for MR, although in certain cases, there are grave risks associated with the surgery. Till now, patients have had to resort to medical treatment to deal with MR, but for patients with specific types of mitral valve dysfunction that leads to MR, clipping the mitral valve will be a good option, especially when the risks of undergoing surgery are dire. Transcatheter mitral valve implantation can help lower the incidences of heart failure and the resulting hospitalizations. It is a less invasive option for patients for whom open-heart surgery is not an option.
Untreated, MR can ultimately result in chronic heart failure, which is the leading reason for hospitalization in Europe and the U.S. It occurs when the mitral valve between two chambers of the heart cannot close completely, and the blood flow leaks backward. It involves symptoms like fatigue, shortness of breath, swollen feet, and inability to exercise or perform daily activities. This leads to increased stress on the heart, enlargement of the heart, heart dysfunction, and even heart failure. The demand for a treatment method is significantly high, which has urged companies and academia to explore the effectiveness of transcatheter mitral valve implantation and is also a major driver for the growth of the market.
The leading companies in the industry include Abbott Laboratories, Medtronic, LivaNova, Edward Lifesciences, MValve Technologies, HLT Medical, Colibri Heart Valve, Neovasc, NeoChord, Biotronik Private Limited, Transcatheter Technologies GmbH and Venus Medtech. The competitive landscape has witnessed numerous deals and developments recently.
Medtronic has partnered with the medical device company incubator, The Foundry, to build and invest in a company dedicated to working on an innovative transcatheter mitral repair (TMVr) technology. The partnership brings together The Foundry’s work in the transcatheter mitral valve repair and replacement field and Medtronic’s position in intellectual property and Structural Heart. The deal creates structured financial tranches from both the companies and gives Medtronic exclusive rights to the resulting corporation dubbed Half Moon Medical, subject to achieving some clinical and technical milestones. Half Moon was also awarded U.S. FDA approval for an early feasibility study in patients having severe and symptomatic MR.
While Half Moon awaits its first implants, another company, TidalHealth, has achieved a medical milestone after successfully implanting MitraClip for treating MR in the heart. Delmarva’s first two implantations of MitraClip were conducted at TidalHealth Peninsula Regional in late September. The number of patients it can benefit will be a primary driver for the growth of the transcatheter mitral valve implantation market in the coming years, especially in regions like Europe and North America that have a high active patient count.